CVS Health Signals Strong 2026 Profit Outlook Amid Turnaround Progress 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Oil Prices Rebound in Asia as Venezuela Sanctions Risks Offset Ukraine Peace Hopes 
Brazil Holds Selic Rate at 15% as Inflation Expectations Stay Elevated 
Asian Stocks Slip as Oracle Earnings Miss Sparks AI Profitability Concerns 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Modi and Trump Hold Phone Call as India Seeks Relief From U.S. Tariffs Over Russian Oil Trade 
Global Markets Slide as Tech Stocks Sink, Yields Rise, and AI Concerns Deepen 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
US Signals Openness to New Trade Deal as Brazil Shows Willingness, Says USTR Greer 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Ireland Limits Planned Trade Ban on Israeli Settlements to Goods Only 
Fed’s Dovish Tone Sends Dollar Lower as Markets Price In More Rate Cuts 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Merck KGaA has signed partnership deals with BenevolentAI and Exscientia for its AI-driven drug discovery push. The German science and technology company is collaborating with these AI drug discovery firms to strengthen its own capabilities in designing and creating new drugs using artificial intelligence.
As per Fierce BioTech, Merck KGaA is betting on an AI-enabled future for drug discovery the new deals with BenevolentAI and Exscientia are part of its strategy to meet its own goals. Based on the reports, the contracts are worth over $30 million upfront and up to $1 billion in possible milestone arrangements.
In any case, with its collaborations with two leading AI drug discovery groups, Merck just bolstered its chances of yielding successful results for its targeted development and production of new drugs on three leading categories in the medical fields, which are immunology, neuroinflammation, cancer, and neurology
Merck’s global head of R&D also said that the incorporation of science, AI, and data could allow them to find and produce “previously unimaginable medical breakthroughs.” Although the AI-enabled drug discovery method is still in the early stages, the company is positive that it will achieve its goals while also becoming a pioneer in this field.
“With the convergence of science, data, and AI, we're determined to fast-track the development of new and truly innovative candidates, forging a path to previously unimaginable medical breakthroughs,” Merck’s global head of research and development and chief medical officer for the healthcare business unit, Danny Bar-Zohar, said in a press release.
He added, “The partnerships with industry-leading AI technology firms BenevolentAI and Exscientia will complement our internal research capabilities and expertise, aligning with our broader strategy to enhance R&D productivity and the output of our pipeline in a sustainable manner.”
Photo by: Merck Group Media Gallery
